Re Shape Lifesciences Inc. RSLS
We take great care to ensure that the data presented and summarized in this overview for ReShape Lifesciences Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RSLS
Top Purchases
Top Sells
About RSLS
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Insider Transactions at RSLS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 31
2024
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
48
-0.21%
|
$0
$0.25 P/Share
|
Feb 29
2024
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
43
-0.19%
|
$0
$0.17 P/Share
|
Dec 31
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
42
-0.18%
|
$0
$0.25 P/Share
|
Nov 30
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
39
-0.17%
|
$0
$0.23 P/Share
|
Oct 25
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
131
-0.57%
|
$0
$0.27 P/Share
|
Oct 11
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
39
-0.17%
|
$0
$0.93 P/Share
|
Sep 01
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
118
-0.51%
|
$0
$0.89 P/Share
|
Aug 24
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
39
-0.17%
|
$39
$1.42 P/Share
|
Aug 04
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
108
-0.46%
|
$108
$1.43 P/Share
|
Jul 06
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
106
-0.45%
|
$106
$1.47 P/Share
|
Jun 30
2023
|
Thomas Stankovich Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
17,702
+42.97%
|
$17,702
$1.52 P/Share
|
May 31
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
98
-1.67%
|
$196
$2.41 P/Share
|
Apr 30
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
96
-1.6%
|
$192
$2.36 P/Share
|
Mar 31
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
109
-1.79%
|
$218
$2.6 P/Share
|
Feb 28
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
103
-1.66%
|
$412
$4.25 P/Share
|
Feb 02
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
157
-2.47%
|
$2,041
$13.29 P/Share
|
Jan 24
2023
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
158
-1.22%
|
$1,106
$7.49 P/Share
|
Dec 01
2022
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,357
-1.11%
|
$0
$0.15 P/Share
|
Nov 28
2022
|
Thomas Stankovich Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
364,756
-52.29%
|
$0
$0.17 P/Share
|
Nov 17
2022
|
Thomas Stankovich Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
364,756
+34.34%
|
-
|
Last 12 Months Summary
Open market or private sale | 91 shares |
---|